Results 91 to 100 of about 24,516 (282)

HUS and atypical HUS [PDF]

, 2017
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin-producing Escherichia coli (STEC) infection,
Al-Nouri, Allen, Amaral, Ardissino, Arvidsson, Atefi, Atkinson, Berry, Bhakdi, Bhattacharjee, Boltax, Brady, Bresin, Bruneau, Bu, Caires, Campistol, Canalejo, Carson, Chapin, Chien, Cofiell, Cole, Conway, Conway, Coppo, Cornec-Le Gall, de Córdoba, Del Conde, Delvaeye, Dempsey, Devine, Dhakal, Dragon-Durey, Egbor, El-Husseini, Faguer, Fakhouri, Ferreira, Ferreira, Fremeaux-Bacchi, Frimat, George, Gilbert, Gorsuch, Gottschalk, Grabowski, Greenbaum, Hill, Hornung, Hosler, Huber-Lang, Hughson, Hyvärinen, Iida, Ikeda, Jin, Jokiranta, Kang, Karnchanaphanurach, Karpman, Karpman, Karpman, Kavanagh, Keir, Kielstein, Kim, Kourouklaris, Krisinger, Kronbichler, Laurence, Law, Lechner, Lehtinen, Lemaire, Licht, Liszewski, Loirat, Lupu, Manuelian, Martel, Mathew, Matsukuma, Mele, Meri, Morton, Moskovich, Mukhopadhyay, Nakakuma, Nester, Noris, Noris, Noris, Oikonomopoulou, Orth-Höller, Ozaki, Pangburn, Pangburn, Pape, Pecoraro, Pilzer, Podack, Ricklin, Rinder, Rodríguez-Pintó, Roumenina, Ruggenenti, Schutte, Scully, Sethi, Sims, Sinha, Song, Ståhl, Ståhl, Sung, Szilágyi, T. Sakari Jokiranta, Tawadrous, Tedesco, Thomas, Thurman, Toh, Tsai, Tufano, Vasu, Ward, Warwicker, Wehling, Wetsel, Whaley, Wiedmer, Wig, Woodworth, Zipfel, Zipfel   +135 more
core   +1 more source

Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis

Open Forum Infectious Diseases, 2023
Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
O. Lortholary, Carine El-Sissy, J. Leporrier, Sarah Sze Wah Wong, E. Dannaoui, V. Frémeaux-Bacchi, V. Aimanianda   +6 more
semanticscholar   +1 more source

Thrombotic microangiopathy and associated renal disorders [PDF]

, 2012
Thrombotic microangiopathy (TMA) is a pathological process involving thrombocytopenia, microangiopathic haemolytic anaemia and microvascular occlusion.
Barbour, T, Cohney, S, Hughes, P, Johnson, S   +3 more
core   +1 more source

Eculizumab in myasthenia gravis: A review

Saudi Journal of Ophthalmology
Eculizumab, a monoclonal antibody against complement C5, is a novel therapy to treat refractory myasthenia gravis (MG). The present review was undertaken to study the role of eculizumab in MG.
Avery W. Zhou, Sabrina Ho, Aroucha Vickers   +2 more
semanticscholar   +1 more source

Eculizumab versus rituximab in generalised myasthenia gravis

Journal of Neurology Neurosurgery & Psychiatry, 2022
Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse.
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, M. Pawlitzki, Liesa Regner-Nelke, Niklas Huntemann, Ercan Arat, Menekşe Öztürk, N. Melzer, P. Mergenthaler, A. Gassa, H. Stetefeld, M. Schroeter, B. Berger, A. Totzeck, T. Hagenacker, S. Schreiber, S. Vielhaber, H. Hartung, A. Meisel, H. Wiendl, S. Meuth, T. Ruck   +22 more
semanticscholar   +1 more source

Role for Complement C5 in Eosinophilic Inflammation of Severe Asthma

Allergy, EarlyView.
Complement activation module, particularly C5, is positively associated with eosinophilic inflammation in severe asthma cohorts. Elevated C5 expression correlates with poor lung function improvement and persistent eosinophilic inflammation. Mouse model studies confirm that C5 exacerbates eosinophilic inflammation, highlighting its potential as a ...
Cong Dong, Shaohua Lu, Zhenan Deng, Xuliang Cai, Huahao Shen, Guochao Shi, Changxing Ou, Zuofu Peng, Wei Jiang, Xiuhua Fu, Changzheng Wang, Meiling Jin, Zhongmin Qiu, Xiaoyang Wei, Wei Gu, Kewu Huang, Qiang Li, Xiangyan Zhang, Nanshan Zhong, Kian Fan Chung, Qingling Zhang, on behalf of C‐BIOPRED Consortium, Jiangtao Lin, Yongming Zhang, Nan Su, Xiaoyan Zhang, Qing Zhao, Ying Nong, Ping Chen, Tianyi Zhu, Binbin Ji, Yan Wang, Haitao Zhao, Jinbao Wang, Zhiyuan Zhang, Xiaona Yang, Chunhua Wei, Jing Han, Nong Yu, Qiang Li, Zhifu Yang, Yanhong Liu, Guohua Li, Huadong Guan, Shuping Zhang, Xiuhua Fu, Lihong Wang, Lingxin Meng, Zhenting Sun, Guangqin Cao, Lei Zhao, Kewu Huang, Hong Zhang, Wen Wang, Li An, Yangyu Chen, Yanli Gao, Xiaoxia Liu, Huifen Zhai, Fang Lin, Zhaohui Zhong, Zhongguang Wen, Yan Xiao, Jian Kang, Linfei Kong, Xinming Su, Xue Yan, Dijia Zhou, Huaping Tang, Wei Han, Yi Shu, Tintian Li, Lixin Xie, Hong Hu, Bo Liu, Yuzhu Li, Longmei Fan, Yue Zhang, Shifeng Zhao, Xiaofang Liu, Yuhong Wang, Xichun Zhang, Xinmao Wang, Pen Bai, Guangfa Wang, Yan Hu, Zhanwei Hu, Ju Cao, Bei He, Rui Wu, Xiaoyan Gai, Hong Zhu, Zhihai Han, Jiyi Meng, Wei Chen, Li Ma, Zhenqian Liu, Chunyang Zhang, Yan Zhang, Huahao Shen, Fugui Yan, Bin Shen, Xinghong Wang, Hao Zhang, Yinghua Yin, Jinkai Liu, Yanxiong Mao, Mao Huang, Xin Yao, Mao Huang, Ji Zhou, Zhenzhen Wu, Ping Yan, Yujie Zhang, Xinling Yang, Ningfei Ji, Fan Fei, Wanzhen Fu, Yi Yang, Yuting Shi, Wangjian Cha, Guochao Shi, Min Zhou, Wei Tang, Wei Chen, Jun Zhou, Wenjie Yang, Lei Zhu, Meiling Jin, Liping Xue, Li Li, Chun Li, Yin Gong, Qiang Li, Guogang Xie, Luhong Bao, Wuping Bao, Nianyun Li, Fengming Ding, Min Zhang, Zhongmin Qiu, Li Yu, Jungang Xie, Lingling Yi, Xianghuai Xu, Qiang Chen, Junjun Tang, Jinfu Xu, Xiaobing Ji, Jingyun Shi, Bo Su, Xiaojun Yang, Jiuwen Bai, Shuo Liang, Kebing Cheng, Wei Gu, Jiyong Ma, Yun Liu, Jun Ren, Shan Mao, Qingling Zhang, Baoqing Sun, Jiaxing Xie, Rihuang Qiu, Zhiqiang Wang, Peiyan Zhen, Wenting Luo, Changgao Zhong, Wei Luo, Yanqing Xie, Xinxin Yu, Wenting Yu, Wei He, Changzheng Wang, Qianli Ma, Min Wan, Mingzhou Zhang, Haining Li, Shaoxi Cai, Haijin Zhao, Yanmei Ye, Fang Zhou, Laiyu Liu, Guohua Huang, Jianpeng Liang, Jianping Zhao, Jungang Xie, Qiongjie Hu, Kaiyan Li, Wang Ni, Guohua Zheng, Weining Xiong, Lingling Yi, Xihu Du, Yunhui Zhang, Zhi Li, Xiaoqiong Tan, Feng Liao, Shenglan Wang, Yijiang Huang, Xinjun Cai, Kai Liu, Shaojing Sheng, Yihui Fu, Shenghua Sun, Qiang Zhang, Jinweng Cai, Ye Ling, Pin Chen, Hong Luo, Lv Liu, Zhijun Liu, Yuling Tang, Yusheng Yan, Guiyan Mo, Long Wen, Yinqun Zhu, Du Fan   +217 more
wiley   +1 more source

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

eJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea   +10 more
doaj   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source

The PNH French Working Group Experience: Building a Strong Network of Cytometrists

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The PNH working group was created in 2010 to initiate a workshop on testing white blood cells to share international recommendations. Methods Thirty‐five French and Belgian laboratories equipped with 2‐ or 3‐laser cytometers applied three different panels with or without FLAER reagent in 305 samples.
Orianne Wagner‐Ballon, Magali Le Garff‐Tavernier, Rémi Lestestu, Bernard Drenou, Agathe Debliquis, the PNH French Working Group «CytHem‐HPN», Chantal Fossat, Claire Loosen, Bernard Chatelain, Marie Loosveld   +9 more
wiley   +1 more source

The Efficacy of Eculizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study

Cureus
Eculizumab, a monoclonal antibody against complement C5, has been approved to prevent neuromyelitis optica spectrum disorder (NMOSD) relapse. Although complement activation leads to neuroinflammation and tissue necrosis in NMOSD attacks, clinical reports
Mitsuru Watanabe, K. Masaki, Eizo Tanaka, T. Matsushita, Noriko Isobe   +4 more
semanticscholar   +1 more source